A Clinical Trial Evaluating the Addition of a Drug, Onartuzumab, to standard treatment (Erlotinib) in Patients with a Specific Generic Type of Lung Cancer

Update Il y a 4 ans
Reference: EUCTR2013-000868-29

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

- To determine the efficacy of onartuzumab+erlotinib compared with placebo+erlotinib, as measured by progression-free survival (PFS) assessed by the investigator.


Inclusion criteria

  • non-small cell lung cancer